Baird Maintains Neutral on Beta Bionics, Lowers Price Target to $14
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and lowers the price target from $28 to $14.
Baird analyst Jeff Johnson maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and lowers the price target from $28 to $14.